An 18-Month, Open-Label Extension Study of Once-Daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES).
Phase of Trial: Phase III
Latest Information Update: 18 Nov 2015
At a glance
- Drugs Parathyroid hormone (Primary)
- Indications Postmenopausal osteoporosis
- Focus Adverse reactions
- Acronyms TRES
- Sponsors NPS Pharmaceuticals
- 11 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 01 Aug 2009 New trial record